Breast Cancer Clinical Trial

A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 1)

Summary

The purpose of this clinical research study is to study the safety of Epofolate (BMS-753493) in patients with advanced cancers (in Phase 1 portion) and to determine whether Epofolate (BMS-753493) can shrink or slow the growth of the cancer in patients with advanced ovarian, renal or breast cancer (in Phase 2 portion).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Advanced cancer, excluding cancer in the blood
Availability of 10 tumor tissue slides

Exclusion:

Known brain metastases
Severe nerve damage
Significant cardiovascular disease
Inadequate blood counts
Inadequate liver or kidney function
Inadequate thyroid function or uncontrolled thyroid disease

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

26

Study ID:

NCT00546247

Recruitment Status:

Terminated

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 4 Locations for this study

See Locations Near You

Lombardi Comprehensive Cancer Center
Washington District of Columbia, 22057, United States
Memorial Sloan Kettering Cancer Center
New York New York, 10021, United States
Fox Chase Cancer Center
Philadelphia Pennsylvania, 19111, United States
Local Institution
Rotterdam , 3075 , Netherlands

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

26

Study ID:

NCT00546247

Recruitment Status:

Terminated

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider